ARS Pharmaceuticals, Inc. SPRY
3.05 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
3.11 +0.06 +1.97%
After hours · Nov 4, 4:00 PM ET
3.00 Day range 3.23
2.91 52-week range 13.15
- YTD
- -73.82%
- 1 year
- -64.98%
- Market cap
- 303.31M
- Revenue (ttm)
- 98.99M
- Profit margin
- -200.00%
- EPS (ttm)
- -2.18
- Shares out
- 99.30M
- Forward P/E
- -11.01
- YTD return
- -73.82%
- 1-year return
- -64.98%
- Volume
- 2.49M
- Avg volume
- 1.66M
- Open
- 3.13
- Previous close
- 3.05
- Day's range
- 3.00 – 3.23
- 52-week range
- 2.91 – 13.15
- Beta
- 0.83
- Price target
- 28.80 (+844.3%)
- Earnings date
- Aug 13, 2026
2Y -12.27 (-80.09%)
Key statistics
- Enterprise value
- 991.06M
- PEG ratio
- 0.00
- Price / sales
- 10.57
- Price / book
- 9.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 184.50%
- Free cash flow
- -98.28M
- Total cash
- 200.97M
- Total debt
- 171.20M
- Return on equity
- -136.40%
- Short % of float
- 37.04%
- 50-day average
- 8.64
- 200-day average
- 9.38
Analyst view
Price target (mean) 28.80 +844.3% upside
Now 3.05
- Target (low)
- 25.00
- Target (mean)
- 28.80
- Target (high)
- 32.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy0
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2026
Expected Aug 13, 2026. Consensus EPS estimate -0.53.
Financials — quick view
SPRY Revenue — quarterly 33.66M
SPRY Net income — quarterly -62.34M
SPRY EPS — quarterly -0.63
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 13, 2026 | Jun 30, 2026 | -0.47655 | — | — | — |
| May 15, 2026 | Mar 31, 2026 | -0.53 | -0.61 | -0.08 | -15.09% |
| Mar 9, 2026 | Dec 31, 2025 | -0.42 | -0.42 | 0.00 | 0.00% |
| Nov 10, 2025 | Sep 30, 2025 | -0.45 | -0.52 | -0.07 | -15.56% |
| Aug 13, 2025 | Jun 30, 2025 | -0.41 | -0.46 | -0.05 | -12.20% |
| May 14, 2025 | Mar 31, 2025 | -0.35 | -0.35 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Sep 4, 2025 | Roth Capital | init | — | Buy |
| Mar 7, 2025 | Scotiabank | init | — | Sector Outperform |
| Jan 14, 2025 | Raymond James | main | Strong Buy | Strong Buy |
| Jan 13, 2025 | Leerink Partners | main | Outperform | Outperform |
| Oct 8, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ars-pharma.com
News
ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling 
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release 
ARS Pharma to Report Third Quarter 2026 Financial Results 
12 Health Care Stocks Moving In Monday's After-Market Session 
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law 
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law 
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026 
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law 
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY 
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
Your note
Sign in to keep a note on SPRY — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FITZPATRICK ALEXANDER A. | Officer | Sale | Jun 11, 2026 | 90,910 |
| FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | Sale | Jun 26, 2025 | 0 |
| KARAS ERIC | Officer | Sale | Jun 11, 2026 | 12,176 |
| LOWENTHAL RICHARD E | Chief Executive Officer | Sale | Aug 20, 2025 | 0 |
| ORBIMED ADVISORS, L.L.C. | Unknown | Sale | Aug 25, 2024 | 0 |
| SCOTT KATHLEEN D | Chief Financial Officer | Sale | Aug 20, 2025 | 18,292 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 10.94% | 10,860,977 | 114.47M | Mar 30, 2026 |
| Orbimed Advisors LLC. | 8.35% | 8,288,510 | 87.36M | Mar 30, 2026 |
| Rubric Capital Management LP | 8.06% | 8,000,000 | 84.32M | Mar 30, 2026 |
| Deerfield Management Company, L.P | 7.56% | 7,503,812 | 79.09M | Mar 30, 2026 |
| Millennium Management Llc | 6.02% | 5,982,919 | 63.06M | Mar 30, 2026 |
| Blackrock Inc. | 5.05% | 5,012,254 | 52.83M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.44% | 2,418,584 | 25.49M | May 30, 2026 |
| abrdn Healthcare Opportunities Fund | 1.80% | 1,783,628 | 18.80M | Mar 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.76% | 1,749,763 | 18.44M | Mar 30, 2026 |
| abrdn Healthcare Investors | 1.56% | 1,548,014 | 16.32M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.40% | 1,393,126 | 14.68M | Apr 29, 2026 |
| BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 1.08% | 1,074,609 | 11.33M | Mar 30, 2026 |